Patient and transplantation characteristics by IA designation
| Characteristic . | Total (n = 2609) . | No IA (n = 2126) . | Proven/probable (n = 483) . | Proven only (n = 194) . | SGM+ only (n = 183) . |
|---|---|---|---|---|---|
| Time to IA diagnosis, median (IQR), d | N/A | N/A | 88 (38.5-204.5) | 86 (43.3-182) | 66 (20.5-122) |
| Median age (IQR), y | 43.9 (32.1-53.1) | 43.2 (31.6-52.4) | 48.1 (34.7-55.5) | 43.7 (31.7-52.0) | 49.4 (36.6-56.9) |
| Diagnosis | |||||
| Acute leukemia | 966 (37.0) | 773 (36.4) | 193 (40.0) | 78 (40.2) | 76 (41.5) |
| CML | 675 (25.9) | 589 (27.7) | 86 (17.8) | 39 (20.1) | 33 (18.0) |
| CLL | 75 (2.9) | 57 (2.7) | 18 (3.7) | 5 (2.6) | 7 (3.8) |
| MDS | 471 (18.1) | 372 (17.5) | 99 (20.5) | 40 (20.6) | 35 (19.1) |
| MM | 143 (5.5) | 111 (5.2) | 32 (6.6) | 12 (6.2) | 15 (8.2) |
| Malignant lymphoma | 279 (10.7) | 224 (10.5) | 55 (11.4) | 20 (10.3) | 17 (9.3) |
| Sex match | |||||
| M-M | 893 (34.2) | 722 (34.0) | 171 (35.4) | 72 (37.1) | 67 (36.6) |
| M-F | 611 (23.4) | 497 (23.4) | 114 (23.6) | 38 (19.6) | 47 (25.7) |
| F-F | 582 (22.3) | 432 (20.3) | 91 (18.8) | 38 (19.6) | 29 (15.8) |
| F-M | 523 (20.0) | 475 (22.3) | 107 (22.2) | 46 (23.7) | 40 (21.9) |
| Stem cell source | |||||
| BM | 1397 (53.5) | 1165 (54.8) | 232 (48.0) | 125 (64.4) | 89 (48.6) |
| Peripheral | 1205 (46.2) | 954 (44.9) | 251 (52.0) | 69 (35.6) | 94 (51.4) |
| Donor type | |||||
| Matched related | 1188 (45.5) | 998 (46.9) | 190 (39.3) | 83 (42.8) | 70 (38.3) |
| Matched unrelated | 957 (36.7) | 775 (36.5) | 182 (37.7) | 69 (35.6) | 70 (38.3) |
| Mismatched | 464 (17.8) | 353 (16.6) | 111 (23.0) | 42 (21.6) | 43 (23.5) |
| Myeloablative | 2125 (82.7) | 1769 (83.2) | 388 (80.3) | 172 (88.7) | 154 (84.2) |
| Disease risk | |||||
| Low | 621 (23.8) | 538 (25.3) | 83 (17.2) | 29 (14.9) | 39 (21.3) |
| Intermediate | 679 (26.0) | 576 (27.1) | 103 (21.3) | 32 (16.5) | 42 (23.0) |
| High | 1154 (44.2) | 889 (41.8) | 265 (54.9) | 126 (64.9) | 88 (48.1) |
| TBI dose | |||||
| None or ≤1200 | 2260 (77.8) | 1572 (73.9) | 394 (81.5) | 132 (68.0) | 162 (88.5) |
| >1200 | 726 (27.8) | 554 (26.1) | 89 (18.4) | 62 (32.0) | 21 (11.5) |
| CMV serostatus | |||||
| R+/D+ | 606 (23.2) | 489 (23.0) | 117 (24.2) | 48 (24.7) | 50 (27.3) |
| R+/D− | 670 (25.7) | 523 (24.6) | 147 (30.4) | 52 (26.8) | 57 (31.1) |
| R−/D+ | 354 (13.6) | 298 (14.0) | 56 (11.6) | 25 (12.9) | 24 (13.1) |
| R−/D− | 979 (37.5) | 816 (38.4) | 163 (33.7) | 69 (35.6) | 52 (28.4) |
| Characteristic . | Total (n = 2609) . | No IA (n = 2126) . | Proven/probable (n = 483) . | Proven only (n = 194) . | SGM+ only (n = 183) . |
|---|---|---|---|---|---|
| Time to IA diagnosis, median (IQR), d | N/A | N/A | 88 (38.5-204.5) | 86 (43.3-182) | 66 (20.5-122) |
| Median age (IQR), y | 43.9 (32.1-53.1) | 43.2 (31.6-52.4) | 48.1 (34.7-55.5) | 43.7 (31.7-52.0) | 49.4 (36.6-56.9) |
| Diagnosis | |||||
| Acute leukemia | 966 (37.0) | 773 (36.4) | 193 (40.0) | 78 (40.2) | 76 (41.5) |
| CML | 675 (25.9) | 589 (27.7) | 86 (17.8) | 39 (20.1) | 33 (18.0) |
| CLL | 75 (2.9) | 57 (2.7) | 18 (3.7) | 5 (2.6) | 7 (3.8) |
| MDS | 471 (18.1) | 372 (17.5) | 99 (20.5) | 40 (20.6) | 35 (19.1) |
| MM | 143 (5.5) | 111 (5.2) | 32 (6.6) | 12 (6.2) | 15 (8.2) |
| Malignant lymphoma | 279 (10.7) | 224 (10.5) | 55 (11.4) | 20 (10.3) | 17 (9.3) |
| Sex match | |||||
| M-M | 893 (34.2) | 722 (34.0) | 171 (35.4) | 72 (37.1) | 67 (36.6) |
| M-F | 611 (23.4) | 497 (23.4) | 114 (23.6) | 38 (19.6) | 47 (25.7) |
| F-F | 582 (22.3) | 432 (20.3) | 91 (18.8) | 38 (19.6) | 29 (15.8) |
| F-M | 523 (20.0) | 475 (22.3) | 107 (22.2) | 46 (23.7) | 40 (21.9) |
| Stem cell source | |||||
| BM | 1397 (53.5) | 1165 (54.8) | 232 (48.0) | 125 (64.4) | 89 (48.6) |
| Peripheral | 1205 (46.2) | 954 (44.9) | 251 (52.0) | 69 (35.6) | 94 (51.4) |
| Donor type | |||||
| Matched related | 1188 (45.5) | 998 (46.9) | 190 (39.3) | 83 (42.8) | 70 (38.3) |
| Matched unrelated | 957 (36.7) | 775 (36.5) | 182 (37.7) | 69 (35.6) | 70 (38.3) |
| Mismatched | 464 (17.8) | 353 (16.6) | 111 (23.0) | 42 (21.6) | 43 (23.5) |
| Myeloablative | 2125 (82.7) | 1769 (83.2) | 388 (80.3) | 172 (88.7) | 154 (84.2) |
| Disease risk | |||||
| Low | 621 (23.8) | 538 (25.3) | 83 (17.2) | 29 (14.9) | 39 (21.3) |
| Intermediate | 679 (26.0) | 576 (27.1) | 103 (21.3) | 32 (16.5) | 42 (23.0) |
| High | 1154 (44.2) | 889 (41.8) | 265 (54.9) | 126 (64.9) | 88 (48.1) |
| TBI dose | |||||
| None or ≤1200 | 2260 (77.8) | 1572 (73.9) | 394 (81.5) | 132 (68.0) | 162 (88.5) |
| >1200 | 726 (27.8) | 554 (26.1) | 89 (18.4) | 62 (32.0) | 21 (11.5) |
| CMV serostatus | |||||
| R+/D+ | 606 (23.2) | 489 (23.0) | 117 (24.2) | 48 (24.7) | 50 (27.3) |
| R+/D− | 670 (25.7) | 523 (24.6) | 147 (30.4) | 52 (26.8) | 57 (31.1) |
| R−/D+ | 354 (13.6) | 298 (14.0) | 56 (11.6) | 25 (12.9) | 24 (13.1) |
| R−/D− | 979 (37.5) | 816 (38.4) | 163 (33.7) | 69 (35.6) | 52 (28.4) |
BM, bone marrow; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; D+, donor seropositive; D−, donor seronegative; F, female; IQR, interquartile range; M, male; MDS, myelodysplastic syndrome; MM, multiple myeloma; N/A, not applicable; R+, recipient seropositive; R−, recipient seronegative; TBI, total body irradiation.